{"contentid": 488297, "importid": NaN, "name": "Market frets over \"deficiencies\" in teplizumab submission", "introduction": "Stock in Provention Bio fell 35% ahead of trading on Friday, after the firm reported a regulatory setback related to its novel diabetes med teplizumab.", "content": "<p>Stock in Provention Bio (Nasdaq: PRVB) fell 35% ahead of trading on Friday, after the firm reported a regulatory setback related to its novel diabetes med teplizumab.</p>\n<p>In a statement, the firm said the US Food and Drug Administration had \"identified deficiencies\" in an ongoing review of the firm&rsquo;s Biologic License Application (BLA) for teplizumab.</p>\n<p>While these deficiencies would &ldquo;preclude discussion of labeling and post-marketing requirements/commitments at this time,&rdquo; they do not indicate a final negative decision from the US regulator.</p>\n<p>The FDA also had bad news for Provention in relation to its single, low-dose bridging study, which compares the firm&rsquo;s planned drug product, manufactured by AGC Biologics, with the drug substance use in its trial program, which is manufactured by Eli Lilly (NYSE: LLY).</p>\n<p>The agency stated that, based on the data it has reviewed to date, it did not view the pharmacokinetic profiles of the two drug products as being comparable, and that additional data would be required.</p>\n<p>These issues would be discussed concurrently with its ongoing review, the FDA said.</p>\n<h2>Bumpy road</h2>\n<p>Formerly under development by fellow US biotech MacroGenics (Nasdaq: MGNX), work on teplizumab was stopped in 2010 after a clinical trial run with partner Eli Lilly failed to show a slowing in the progression of diabetes.</p>\n<p>Provention acquired all rights to the compound under the terms of a deal agreed in 2018, which also included licensing rights to MGD010, seen as a potential treatment for systemic lupus erythematosus (SLE).</p>\n<p>Given the burden associated with type 1 diabetes, analysts have estimated a course of treatment could be priced at around $100,000, on which basis teplizumab would secure blockbuster status if it achieves the expected level of market penetration.</p>\n<p>Commenting on the recent regulatory setback, chief executive Ashleigh Palmer said the FDA's initial feedback &ldquo;will likely result in a delay in timelines&rdquo; for the potential approval of teplizumab in type 1 diabetes.</p>\n<p>He added: &ldquo;We believe in the comparability of the drug product produced by our partner AGC biologics with Eli Lilly manufactured product,&rdquo; adding: &ldquo;We look forward to working closely with the agency to address its additional data requirement, so we can deliver teplizumab to patients as soon as possible.\"</p>", "date": "2021-04-09 16:40:00", "meta_title": NaN, "meta_keywords": "teplizumab, diabetes, drug, Provention, deficiencies, firm, setback, regulatory, market, frets, submission, reported, Friday, related, trading, fell, Stock", "meta_description": "Stock in Provention Bio fell 35% ahead of trading on Friday, after the firm reported a regulatory setback related to its novel diabetes med teplizumab.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-09 14:13:10", "updated": "2021-04-09 18:30:04", "access": NaN, "url": "https://www.thepharmaletter.com/article/market-frets-over-deficiencies-in-teplizumab-submission", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "provention-bio-large.jpg", "image2id": "provention-bio-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Diabetes", "topic_tag": "Drug Trial, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "Provention Bio", "drug_tag": "teplizumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-09 16:40:00"}